GGrantIndex
← Leaderboards

Lovelace Biomedical Research Institute

Albuquerque, NM

Compare ↔
$48,026,004
Total funding
40
Grants

Funding over time

peak $13.7M · FY2020–25
$20M$15M$10M$5M$0
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$43,853,943 · 36
DOD$4,172,061 · 4

By mechanism

R01$26,868,982 · 16
N01$7,056,614 · 8
—$4,172,061 · 4
P30$3,938,471 · 5
U01$2,414,128 · 1
UG3$899,869 · 1

Investigators at Lovelace Biomedical Research Institute

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Sephira Ryman$2,999,4792 gr2Andrei A Vakhtin$2,171,4431 gr3Felicha Candelaria-Cook$733,7041 gr4Olga A Bragina$596,7501 gr

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

1Fadi Xu$10,847,0476 gr2Sephira Ryman$2,999,4792 gr3Andrei A Vakhtin$2,171,4431 gr4Felicha Candelaria-Cook$733,7041 gr5Olga A Bragina$596,7501 gr

Largest grants

NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA, MMAB)$2,024,745
N01 · FY2025 · OD
EFFICACY AND SAFETY EVALUATION OF LEAD GENE THERAPY CANDIDATE IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT$1,595,870
N01 · FY2023 · DA
A PROSPECTIVE OBSERVATIONAL STUDY ON THERAPEUTIC AND ADVERSE EFFECTS OF MEDICAL CANNABIS FOR CHRONIC TRAUMATIC BRAIN INJURY$1,499,922
· FY2022 · Department of the Army
Phase III COBRE: Multimodal Imaging of Neuropsychiatric Disorders (MIND)$1,329,407
P30 · FY2020 · GM
Phase III COBRE: Multimodal Imaging of Neuropsychiatric Disorders (MIND)$1,329,407
P30 · FY2022 · GM
Phase III COBRE: Multimodal Imaging of Neuropsychiatric Disorders (MIND)$1,318,547
P30 · FY2021 · GM
GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY$1,254,413
N01 · FY2022 · HL
A NOVEL ADVANCED RESUSCITATION FLUID FOR A SWINE POLYTRAUMA MODEL (TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK)$1,086,750
· FY2025 · Defense Health Agency
Mechanism and Countermeasure of Fentanyl-Induced Sudden Death$944,202
R01 · FY2025 · HL
Mechanism and Countermeasure of Fentanyl-Induced Sudden Death$940,773
R01 · FY2023 · HL
Multimodal prediction of behavioral and mental health outcomes in incarcerated women$904,100
R01 · FY2025 · MH
Applying Neuromodulation to Boost the Efficacy of Motivational Interviewing$899,869
UG3 · FY2025 · DA
Mechanism and Countermeasure of Fentanyl-Induced Sudden Death$897,591
R01 · FY2024 · HL
Microbiome-gut-brain dysfunction in prodromal and symptomatic Lewy body diseases$890,110
R01 · FY2024 · NS
Microbiome-gut-brain dysfunction in prodromal and symptomatic Lewy body diseases$889,363
R01 · FY2025 · NS
The synchrony study: A randomized controlled trial of music training for children$852,356
R33 · FY2025 · AA
EFFECTS OF ALTITUDE DURING ROTARY WING TRANSPORT IN A LARGE-ANIMAL POLYTRAUMA MODEL$850,776
· FY2022 · Defense Health Agency
DNA Repair Capacity Assays for Lung Disease Risk Assessment$832,058
U01 · FY2021 · CA
The Impact of Diffuse Mild Brain Injury on Clinical Outcomes in Children$821,974
R01 · FY2025 · NS
Microbiome-gut-brain dysfunction in prodromal and symptomatic Lewy body diseases$815,866
R01 · FY2023 · NS